
ACM BIOLABS ANNOUNCES INVESTMENT AND EXCLUSIVE TECHNOLOGY LICENSE

Singapore, 13th April 2016 – ACM Biolabs announced today that it has received an exclusive technology license and an investment from NTUitive, the commercialization arm of the Nanyang Technological University, Singapore (“NTU Singapore”).

The licensed technology is primarily focused on the use of artificial cell membranes in pharmaceutical delivery (also known as “drug delivery”) applications. It is particularly promising for transdermal drug delivery (i.e. delivering pharmaceuticals through the patient’s skin). The technology was co-developed by ACM Biolabs and NTU's School of Materials Science and Engineering during a 2-year collaboration.

Dr. Lim Jui, CEO of NTUitive said, “We have been following the progress of Dr. Nallani and ACM Biolabs for a considerable time and have been impressed with the leading technology platform they have developed and the excellent traction they have achieved with global pharma companies. We firmly believe that they will continue to go from strength to strength. We are delighted to partner them in technology development and also as a shareholder.”

Dr. Madhavan Nallani, CEO of ACM Biolabs, commented “We have benefited tremendously from the ongoing collaboration with NTU and its world-class facilities and staff and the investment will help to cement our already strong relationship. The exclusive license to the jointly developed technology further strengthens our growing intellectual property position. In addition, the technology developed adds some new dimensions to our capabilities, such as the potential to do transdermal drug delivery.”

About ACM Biolabs Pte Ltd

ACM Biolabs is a synthetic biology company using its proprietary Artificial Cell Membrane (“ACM”) technology platform to allow its customers to develop diagnostics, therapeutics and vaccines targeting novel membrane proteins. ACM technology is being used by the world’s leading pharmaceutical companies to develop products requiring membrane proteins that are difficult or impossible to work with using traditional methods. ACM Biolabs has licensed technology from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research agency.

About Nanyang Technological University (NTU Singapore)

A research-intensive public university, Nanyang Technological University, Singapore (NTU Singapore) has 33,500 undergraduate and postgraduate students in the colleges of Engineering, Business,

Science, Humanities, Arts, & Social Sciences, and its Interdisciplinary Graduate School. It has a new medical school, the Lee Kong Chian School of Medicine, set up jointly with Imperial College London.

NTU is also home to world-class autonomous institutes – the National Institute of Education, S Rajaratnam School of International Studies, Earth Observatory of Singapore, and Singapore Centre on Environmental Life Sciences Engineering – and various leading research centres such as the Nanyang Environment & Water Research Institute (NEWRI), Energy Research Institute @ NTU (ERI@N) and the Institute on Asian Consumer Insight (ACI).

Ranked 13th in the world, NTU has also been ranked the world's top young university for the last two years running. The University's main campus has been named one of the Top 15 Most Beautiful in the World. NTU also has a campus in Novena, Singapore's medical district.

For more information, visit www.ntu.edu.sg

Media Contact:

Peter Moran
ACM Biolabs Pte Ltd
peter.moran@ACMBiolabs.com